Rd Funding Sample Clauses

Rd Funding. Biogen Idec shall make a [****] non-creditable, non-refundable R&D funding payment to PDL within [****] after approval by the JSC of a [****] to the JSC following the Effective Date.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Rd Funding. During the period commencing on the Effective Date and continuing on a Licensed Product by Licensed Product basis until the earlier of (a) the exercise by ImmunoGen of a Co-Development Option with respect to such Licensed Product and (b) the expiration of the Research Program term, Biotest shall pay ImmunoGen the aggregate FTE Cost for all FTEs used by ImmunoGen in the conduct of ImmunoGen Activities on a quarterly basis, based on the FTE Rate and the Research Plan and/or Development Plan. Within [***] ([***]) days following the last day of each Calendar Quarter during the conduct of the Research Program, ImmunoGen shall issue an invoice reflecting the FTE Costs for such Calendar Quarter, as reflected in the then-current Research Plan and Biotest shall pay each such invoice within [***] ([***]) days from receipt. The amount invoiced for ImmunoGen Activities performed by an FTE shall be calculated based on [***] [***] [***] using an [***] [***] [***] and [***] of [***] in a [***] [***] [***] the [***] of [***] [***] [***] such ImmunoGen Activities, based on a total of [***] hours in an FTE year. Such invoice shall have attached to it a copy of the [***] [***] [***] of [***] [***] [***] to the [***] [***] on such particular invoice. If, at any time during the Term of this Agreement, ImmunoGen determines that the actual number of FTEs for a particular Calendar Quarter agreed to by the Parties is expected to exceed by [***] percent ([***]%) the [***] [***] set forth in such Research Plan for such Calendar Quarter, ImmunoGen shall give Biotest prompt written notice of same and the Parties shall discuss in good faith whether to [***] the [***] of such [***] [***] or to [***] the [***] to be [***], such that such [***] [***] are [***] [***]. The JDC shall be the forum for discussions about an extension of ImmunoGen Activities not covered by the budget as laid down in the Research Plan.
Sample 1Sample 2
Rd Funding. In addition to the milestone payments due under Section ----------- 7.1 hereof, SP Ltd. agrees to reimburse Zonagen for the reasonable actual out- of-pocket expenses (which have not otherwise been reimbursed by Schering Corporation pursuant to the U.S. License Agreement) Zonagen has incurred or incurs in conducting the ongoing open-label study of the Licensed Product, which open-label study is identified by Zonagen as Study ZON303. Notwithstanding the foregoing, SP Ltd.'s total obligation to reimburse Zonagen in accordance with this Section 7.2 shall not exceed ***. SP Ltd.'s reimbursement of such expenses pursuant to this Section 7.2 will be made in installments, pursuant to invoices submitted by Zonagen to SP Ltd., which invoices shall include documentation (including, without limitation, invoices Zonagen has received from third parties) that supports the amount of expenses for which SP Ltd. is being invoiced. Zonagen shall submit to SP Ltd. an invoice for the first such installment upon the filing with the FDA of an NDA supporting U.S. Regulatory Approval of the Licensed Product, which installment, subject to the limitations set forth in this Section 7.2, shall be in the amount of such actual out-of- pocket expenses incurred by Zonagen prior to such time. Thereafter, Zonagen shall submit to SP Ltd. invoices and supporting documentation within thirty (30) days after the end of each Calendar Quarter, which invoices, subject to the limitations set forth in this Section 7.2, shall be for the reasonable actual out-of-pocket expenses incurred by Zonagen during such Calendar Quarter. Each such invoice shall be payable within sixty (60) days after SP Ltd.'s receipt of the invoice. *** This portion has been omitted based on a request for confidential treatment pursuant to Rule 24b-2 of the Exchange Act. The omitted portion has been separately filed with the Commission.
Sample 1
Rd Funding. Funding of the research under the Projects shall be in accordance with Section 3.5 as further outlined in the Work Plan and applicable Project Plans. 6.3. [***] 6.4.
Sample 1
Rd Funding. No funding, facilities or resources of any government, military, university, college, other educational institution or research center (“R&D Sponsor”) was or is used in the development of the Company Products, Owned Company Intellectual Property or Technology owned or purported to be owned by the Company Group, and no employee or contractor who developed or created any Owned Company Intellectual Property was employed by or has performed services for any R&D Sponsor during the period of time during which such Person was also performing services for the Company Group, in each case, in a manner that would grant such R&D Sponsor any rights to any Company Intellectual Property. No R&D Sponsor has made in writing any claim of right to, ownership of or other Lien on any Owned Company Intellectual Property. Section 3.18(k) of the Disclosure Schedule sets forth a list of all agreements between a member of the Company Group and a R&D Sponsor relating to the development of the Company Products, Owned Company Intellectual Property or Technology that was in effect at any time since the date that is five (5) years prior to the date of this Agreement.
Sample 1

Related to Rd Funding

  • Research Funding Genocea shall pay to Isconova in total [* * *] payable as follows: (i) $[* * *] in equal monthly installments for each remaining month in 2009 following the Effective Date and (ii) $[* * *] in equal monthly installments during the period from January 1, 2010 until March 31, 2012. The Research Funding shall be used solely for the performance of activities under the Research and Phase 1 Supply Plan and the Development and Scale-Up Plan and, for the avoidance of doubt, solely to fund Development and research activities for human (and not veterinary) applications in accordance with such Research and Phase 1 Supply Plan and Development and Scale-Up Plan. Notwithstanding anything to the contrary above, the Parties agree that this restriction shall only apply to the allocation and use of the Research Funding as such, and shall not be construed as limiting or affecting the ownership of any Isconova Technology and Joint Technology created, conceived, reduced to practice or Invented hereunder. Isconova’s ownership and/or rights to the Isconova Technology and Joint Technology shall exclusively be governed by the provisions in Section 3.3. and Isconova’s use of the Isconova Technology and Joint Technology shall be subject only to the licenses granted to Genocea in Sections 3.1.1 through 3.1.3. Isconova shall during the Research Term allocate not less than two (2) dedicated FTEs for Isconova’s research work for Genocea hereunder and each such dedicated FTE shall be paid through Research Funding. During the Research Term, Isconova shall, within fifteen (15) days after the end of each month, deliver to Genocea a report setting forth the number of Isconova FTEs that worked on activities under the Development and Scale-Up Plan and the Research and Phase 1 Supply Plan, as well as other costs and expenses of Isconova evidencing recourses spent on Isconova’s research work hereunder. Researching Funding THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. payments shall be made within fifteen (15) days after the end of each calendar month.

  • Additional Funding If the General Partner determines that it is in the best interests of the Partnership to provide for additional Partnership funds (“Additional Funds”) for any Partnership purpose, the General Partner may (i) cause the Partnership to obtain such funds from outside borrowings, or (ii) elect to have the General Partner or any of its Affiliates provide such Additional Funds to the Partnership through loans or otherwise.

  • Funding This Contract is subject to termination or cancellation, without penalty to System Agency, either in whole or in part, subject to the availability of state funds. System Agency is a state agency whose authority and appropriations are subject to actions of the Texas Legislature. If System Agency becomes subject to a legislative change, revocation of statutory authority, or lack of appropriated funds that would render either System Agency’s or Grantee’s delivery or performance under the Contract impossible or unnecessary, the Contract will be terminated or cancelled and be deemed null and void. In the event of a termination or cancellation under this Section, System Agency will not be liable to Grantee for any damages, that are caused or associated with such termination, or cancellation, and System Agency will not be required to give prior notice.

  • Development Funding (a) Viewray will pay 3D Line the then U.S. Dollar equivalent of €[***] within three (3) days of the Effective Date for the engineering services required to develop/ deliver the Deliverable described in Section 2.1(a)(i).

Time is Money Join Law Insider Premium to draft better contracts faster.